Press Releases
March 2024
03.13.2024 Vaccines Vaccines European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease 03.12.2024 Medicines Research Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) 03.05.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 2024
02.29.2024 Financial Investments Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth 02.29.2024 Vaccines Vaccines Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults 02.26.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.19.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 02.15.2024 Financial Finance Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day 02.12.2024 Corporate Partnerships UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies 02.05.2024 Prescription Medicines Responsibility Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
January 2024
01.30.2024 Corporate Financial Finance Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance 01.26.2024 Prescription Medicines Medicines European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Resource Library
Press Kits
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Contact Pfizer Media Relations
Media Contacts
United States, Canada, and Latin America
+1 212.733.1226
Europe, Middle East, and Africa
+44-(0)845.300.8033
Asia Pacific
+65.918.732.47
Email
[email protected]
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.